Clinical trial NCT05383820: Effect of Paracetamol and Ketorolac on RANK-L Levels in Patients Starting Orthodontic Treatment
Official title: Effect of Paracetamol and Ketorolac on RANK-L Levels in Patients Starting Orthodontic Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Malocclusion
Pain, Acute
Keywords: Orthodontics
RANK-L
Ketorolac
Paracetamol
Gingival crevicular fluid
Lead sponsor: University of Guadalajara
Sponsor class: OTHER
First posted: 2022-05-20
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 27
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A double-blind clinical trial will be carried out with a placebo control group and random drug allocation. Patients who begin orthodontic treatment in the Orthodontic Specialty of the Comprehensive Dental Clinics of the University Center for Health Sciences and who decide to participate in the study with the signing of informed consent will be included. Three groups will be formed with 8 patients in each one.

The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
Primary purpose: BASIC_SCIENCE

Brief summary: Due to the high prevalence of malocclusions in Mexico and the existing concern to improve aesthetics, function (chewing), or both, patients resort to orthodontic treatment. The patient may experience pain during treatment due to the release of different chemical mediators such as RANK-L. Analgesic and anti-inflammatory medications such as acetaminophen and ketorolac are used to control pain during orthodontic tooth movement. These drugs can inhibit the expression of RANK-L which can affect tooth movement, inhibiting bone remodeling. The orthodontist should indicate the drug that is safest for the patient without affecting treatment or tooth movement.

Detailed description: Objective: To evaluate the association of RANK-L levels with the administration of paracetamol and ketorolac in patients starting orthodontic treatment.

Material and methods: A double-blind clinical trial will be carried out with a placebo control group and random drug allocation. Patients who begin orthodontic treatment in the Orthodontic Specialty of the Comprehensive Dental Clinics of the University Center for Health Sciences and who decide to participate in the study with the signing of informed consent will be included. Three groups will be formed with 8 patients in each one.

The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).

Measurements will be made four times; baseline, 24 h, 48 h, and on day 5 of initiation of treatment.

Eligibility criteria: Inclusion Criteria:

* Patients of both sexes between 18 and 27 years of age
* Periodontally and systematically healthy
* Attended the Orthodontic Clinic of the University of Guadalajara
* Who required the use of dental spacers in at least one quadrant were included

Exclusion Criteria:

* Patients who have previously had orthodontic treatment or are under orthodontic treatment
* Who have an allergy to ketorolac or paracetamol
* Who are under pharmacological treatment and/or using contraceptives
* Pregnant or lactating women, as well as those who consume alcohol were not included or tobacco.

Primary outcomes:
measure: Leves RANK-L
timeFrame: Baseline, 24 hours, 48 hours, and on day 5 of initiation of treatment.
Secondary outcomes:
measure: Pain scale
timeFrame: Baseline, 24 hours, 48 hours, and on day 5 of initiation of treatment.
measure: Intermolar Space (IS)
timeFrame: 5 days of initiation of treatment.
Other outcomes:
Locations:
city: Guadalajara
country: Mexico
facility: Juan Ramón Gómez Sandoval
state: Jaisco
Study officials:
References: